Precision BioSciences Presents Preclinical Data Demonstrating Potential of ARCUS for Treatment of Duchenne Muscular Dystrophy at the American Society of Gene & Cell Therapy 26th Annual Meeting
Late-breaking, oral presentation highlights ability of ARCUS gene editing approach to achieve large gene excisions enabling significant functional muscle improvement in preclinical study DURHAM, N.C.…
Precision BioSciences Announces Publication of its Preclinical In Vivo Gene Editing Abstract on Duchenne Muscular Dystrophy Program for the American Society of Gene & Cell Therapy 26th Annual Meeting
Late-Breaking Abstract Demonstrates Capabilities of ARCUS for Large Gene Excision In Vivo DURHAM, N.C. --(BUSINESS WIRE)--May 12, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage…
Precision BioSciences Reports First Quarter 2023 Financial Results and Provides Business Update
- Program Updates Planned for Azer-cel and PBCAR19B in May 2023 - Presented data on PBGENE-HBV program at Global Hepatitis Summit 2023; PBGENE-DMD program data update upcoming at ASGCT Conference -…
Precision BioSciences to Report First Quarter 2023 Results on May 9, 2023
DURHAM, N.C. --(BUSINESS WIRE)--May 2, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene…
Precision BioSciences to Present Preclinical In Vivo Gene Editing Research for its ARCUS HBV Program at Upcoming Global Hepatitis Summit 2023
- Oral Presentation to Highlight Efficacy and Specificity of ARCUS Nucleases for Potential Treatment of Chronic Hepatitis B DURHAM, N.C. --(BUSINESS WIRE)--Apr. 20, 2023-- Precision BioSciences, Inc.…
Precision BioSciences Announces Late-Breaking Abstract of Preclinical In Vivo Gene Editing Research Selected for Oral Presentation at the American Society of Gene & Cell Therapy 26th Annual Meeting
- Presentation to Highlight Preclinical Development Progress of PBGENE-DMD Program for Potential Treatment of Duchenne Muscular Dystrophy DURHAM, N.C. --(BUSINESS WIRE)--Apr. 18, 2023-- Precision…
Precision BioSciences Receives U.S. and International Patent Allowances for Proprietary PCSK9 ARCUS Nuclease
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 13, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene…
Precision BioSciences to Participate in Upcoming Guggenheim Healthcare Talks Conference
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 27, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene…
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
- Advanced ARCUS Gene Editing Development for Clinical and Research Programs; In Vivo Gene Editing R&D Day Planned for Mid-2023 - Progressed Azer-cel and PBCAR19B Allogenic CAR T Clinical…
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2022 Results on March 9, 2023
DURHAM, N.C. --(BUSINESS WIRE)--Mar. 2, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene…
Precision BioSciences Announces Senior Leadership Promotions and Organizational Changes
- Neil Leatherbury Appointed Senior Vice President, Head of CMC – - Derek Jantz , Ph.D., to Assume Advisory Position of Co-Founder and Chief Science Advisor – - Jeff Smith , Ph.D., Co-Founder and…
Precision BioSciences to Participate in Upcoming H.C. Wainwright Cell Therapy Virtual Conference
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 22, 2023-- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene…
Precision BioSciences Recaps 2022 Accomplishments and Outlines 2023 Corporate Priorities and Planned Portfolio Milestones
DURHAM, N.C. --(BUSINESS WIRE)--Jan. 9, 2023-- Precision BioSciences (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ® -based ex vivo allogeneic CAR T and in vivo gene editing…
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate
- FDA feedback signals the Company’s CMC plans shared are in alignment with Agency requirements and expectations - CMC regulatory feedback is a critical step in the pathway for development of…
